In 20–30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. This evidence concerns the gene DPYD and hyperinsulinemic hypoglycemia, familial, 4.